CTI BioPharma Reports Fourth Quarter and Full Year 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
CTI BioPharma (CTIC) Misses Q4 EPS by 4c
March 17, 2021 4:21 PM EDTCTI BioPharma (NASDAQ: CTIC) reported Q4 EPS of ($0.20), $0.04 worse than the analyst estimate of ($0.16).
"This past quarter, CTI has executed on the critical clinical, regulatory and commercial activities that will allow for the potential U.S. approval and commercial launch of... More
